Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket

RAS mutants are major therapeutic targets in oncology with few efficacious direct inhibitors available. The identification of a shallow pocket near the Switch II region on RAS has led to the development of small-molecule drugs that target this site and inhibit KRAS(G12C) and KRAS(G12D). To discover...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallon, Lauren, Khan, Imran, Teng, Kai Wen, Koide, Akiko, Zuberi, Mariyam, Li, Jianping, Ketavarapu, Gayatri, Traaseth, Nathaniel J., O’Bryan, John P., Koide, Shohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618066/
https://www.ncbi.nlm.nih.gov/pubmed/36252024
http://dx.doi.org/10.1073/pnas.2204481119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618066/
https://www.ncbi.nlm.nih.gov/pubmed/36252024
http://dx.doi.org/10.1073/pnas.2204481119

Ejemplares similares